BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Akorn, Inc. (NASDAQ:AKRX) today announced that it has received an approval for alternate manufacturing site for IC-Green™ from the U.S. Food and Drug Administration (FDA). Akorn will begin customer shipments immediately. Currently, the customer order backlog for IC-Green™ is approximately $3.0 million. Of this total, $1.8 million will ship and bill in Q3’07, with the remaining $1.2 million fulfilled in Q4’07. Akorn regrets any inconvenience this drug shortage has created, and is pleased to re-launch IC-Green™ into the marketplace.
